-
公开(公告)号:TWI629077B
公开(公告)日:2018-07-11
申请号:TW103103461
申请日:2014-01-29
Applicant: UCB生物製藥公司 , UCB BIOPHARMA SPRL
-
公开(公告)号:TW201706302A
公开(公告)日:2017-02-16
申请号:TW105114957
申请日:2016-05-13
Applicant: UCB生物製藥公司 , UCB BIOPHARMA SPRL
Inventor: 柏哈塔 帕拉畢 , BHATTA, PALLAVI , 大衛 愛瑪 , DAVE, EMMA , 海伍德 山姆 , HEYWOOD, SAM , 胡弗瑞斯 大衛 , HUMPHREYS, DAVID , 史密斯 布萊恩 , SMITH, BRYAN
CPC classification number: C07K16/283 , A61K2039/505 , A61P7/00 , A61P17/00 , A61P21/04 , A61P25/00 , A61P37/00 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/30 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/74
Abstract: 本揭示係關於對FcRn具有特異性之抗體融合蛋白、包含其之調配物、各於療法中之用途、表現及視情況調配該抗體之方法、編碼該等抗體之DNA,及包含該DNA之宿主。
Abstract in simplified Chinese: 本揭示系关于对FcRn具有特异性之抗体融合蛋白、包含其之调配物、各于疗法中之用途、表现及视情况调配该抗体之方法、编码该等抗体之DNA,及包含该DNA之宿主。
-
公开(公告)号:TW201702271A
公开(公告)日:2017-01-16
申请号:TW105113624
申请日:2016-04-29
Applicant: 哈佛大學校長及研究員協會 , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , UCB生物製藥公司 , UCB BIOPHARMA SPRL
Inventor: 哈特米斯里基 格克翰S , 羅伯特斯 伊麗莎白 海倫 , ROBERTS, ELISABETH HELEN , 穆爾 安德里 理查德 , MOORE, ADRIAN RICHARD , 德理 卡羅 布蘭登 , DOYLE, CARL BRENDAN , 艾當斯 羅夫 , ADAMS, RALPH , 赫夫 凱琳 傑尼 馬德理 , 瓦爾斯 蘇那 海俐 , WALES, SHAUNA MHAIRI , 泰森 凱芮 路易斯 , TYSON, KERRY LOUISE , 沃德馬爾 史考特B , WIDENMAIER, SCOTT B. , 布萊克 瑪瑪特F , BURAK, MEHMET F. , 安傑 菲莎S , ENGIN, FEYZA S.
IPC: C07K16/28 , A61K39/395 , A61P3/00
CPC classification number: C07K16/18 , A61K39/00 , A61K2039/505 , A61K2039/507 , A61K2039/6018 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/70 , C07K2317/76 , C07K2317/92
Abstract: 本發明係關於改良之抗-aP2抗體及抗原結合劑以及其組合物,該等抗體靶向脂質伴護蛋白aP2/FABP4(稱為「aP2」),尤其用於治療諸如糖尿病、肥胖、心血管疾病、脂肪肝及/或癌症之病症。在一個態樣中,揭示改良之aP2介導之病症治療,其中使用低結合親和力之aP2單株抗體,靶向血清aP2且中和或調節aP2之生物活性,提供較低空腹血糖含量、改善全身性葡萄糖代謝、增加全身性胰島素敏感性、降低脂肪量、降低肝臟脂肪變性、減少心血管疾病及/或降低出現心血管疾病之風險。
Abstract in simplified Chinese: 本发明系关于改良之抗-aP2抗体及抗原结合剂以及其组合物,该等抗体靶向脂质伴护蛋白aP2/FABP4(称为“aP2”),尤其用于治疗诸如糖尿病、肥胖、心血管疾病、脂肪肝及/或癌症之病症。在一个态样中,揭示改良之aP2介导之病症治疗,其中使用低结合亲和力之aP2单株抗体,靶向血清aP2且中和或调节aP2之生物活性,提供较低空腹血糖含量、改善全身性葡萄糖代谢、增加全身性胰岛素敏感性、降低脂肪量、降低肝脏脂肪变性、减少心血管疾病及/或降低出现心血管疾病之风险。
-
公开(公告)号:TW201619188A
公开(公告)日:2016-06-01
申请号:TW104107000
申请日:2015-03-05
Applicant: 優稀美生物醫藥公司 , UCB BIOPHARMA SPRL
Inventor: 漢弗瑞斯 大衛保羅 , HUMPHREYS, DAVID PAUL , 法拉阿瑞尼 法那 , FALLAH-ARANI, FARNAZ , 彼得斯 雪麗珍 , PETERS, SHIRLEY JANE , 葛瑞芬 羅伯特安東尼 , GRIFFIN, ROBERT ANTHONY , 史密斯 布萊恩約翰 , SMITH, BRYAN JOHN , 史蒂芬斯 保羅艾德華 , STEPHENS, PAUL EDWARD
IPC: C07K14/435 , C12N15/62 , A61K38/17 , A61P37/00
CPC classification number: C07K16/00 , A61K2039/505 , C07K16/46 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/62 , C07K2317/76 , C07K2317/92 , C12N15/62 , C12P21/02
Abstract: 本發明係關於與人類Fc受體結合之多聚體融合蛋白質。本發明亦關於一種包含該蛋白質之治療性組成物,及其用於治療免疫疾病之用途。
Abstract in simplified Chinese: 本发明系关于与人类Fc受体结合之多聚体融合蛋白质。本发明亦关于一种包含该蛋白质之治疗性组成物,及其用于治疗免疫疾病之用途。
-
公开(公告)号:TW201512221A
公开(公告)日:2015-04-01
申请号:TW103126815
申请日:2014-08-05
Applicant: UCB生物製藥公司 , UCB BIOPHARMA SPRL
Inventor: 魁葛斯 葛萊漢 , CRAGGS, GRAHAM , 哈維 卡琳 珍妮 曼德蘭妮 , 馬修爾 黛安 , MARSHALL, DIANE
IPC: C07K16/28 , A61K39/395 , A61P35/00 , A61P43/00
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: 本發明係關於抗-CSF-1R抗體及其結合片段、編碼其之DNA、包含該DNA之宿主細胞及於宿主細胞中表現該抗體或結合片段之方法。本發明亦關於包含該抗體或其結合片段之醫藥組合物及一種以該抗體、結合片段及包含其之組合物於治療中之用途。
Abstract in simplified Chinese: 本发明系关于抗-CSF-1R抗体及其结合片段、编码其之DNA、包含该DNA之宿主细胞及于宿主细胞中表现该抗体或结合片段之方法。本发明亦关于包含该抗体或其结合片段之医药组合物及一种以该抗体、结合片段及包含其之组合物于治疗中之用途。
-
公开(公告)号:CA2895608A1
公开(公告)日:2014-06-26
申请号:CA2895608
申请日:2013-12-20
Applicant: UCB BIOPHARMA SPRL , UCB BIOPHARMA SPRL
Inventor: DAVE EMMA , HEYWOOD SAM PHILLIP , HUMPHREYS DAVID PAUL
Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.
-
公开(公告)号:US11466076B2
公开(公告)日:2022-10-11
申请号:US16098085
申请日:2017-04-28
Applicant: UCB BIOPHARMA SPRL
Inventor: Ralph Adams , Sam Philip Heywood
IPC: C07K16/00 , C07K16/18 , C07K14/76 , C07K14/765 , C07K16/06 , A61K39/395 , A61K39/00 , C07K16/46
Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
-
公开(公告)号:US11324896B2
公开(公告)日:2022-05-10
申请号:US16608400
申请日:2018-04-25
Applicant: UCB Biopharma SPRL
Inventor: Barry Alan Knight , Marko Plevnik , Norihiko Inoue , Jamie Buckley , Lisa Hornsey
IPC: A61M5/32
Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a cap body defining an inner and outer cap body; provided to the inner cap body, a grip for gripping the needle cover of said syringe; provided to the outer cap body, an opposing pair of recessed portions, wherein each recessed portion defines a recess base, and wherein each recessed portion is bounded by a peripheral lip; and provided to the recess base of each recessed portion, an over-coating. The cap body comprises a generally rigid material and each over-coating comprises a more flexible material. Each peripheral lip defines banks that extend beyond the over-coating of the recess base.
-
公开(公告)号:US11059911B2
公开(公告)日:2021-07-13
申请号:US16242378
申请日:2019-01-08
Applicant: UCB Biopharma SPRL
Inventor: David Paul Humphreys , Shirley Jane Peters
Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain:
the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and
optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.-
30.
公开(公告)号:US20200377578A1
公开(公告)日:2020-12-03
申请号:US16919576
申请日:2020-07-02
Applicant: UCB Biopharma SPRL
Inventor: David Paul Humphreys , Daniel John Lightwood , Kerry Louise Tyson , David Edward Ormonde Knight , Karine Jeannine Madeleine Hervé , Joanne Elizabeth Compson , Matthew Jon Timothy Page , Andrew Charles Payne , Nicola Louise Fisher , Brendon MacKenzie , Matthew Cox
IPC: C07K16/12 , A61K39/40 , A61K45/06 , G01N33/569 , G01N33/573 , G01N33/68
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
-
-
-
-
-
-
-
-
-